Related Experiment Video
Updated: Nov 20, 2025

Echocardiographic and Histological Examination of Cardiac Morphology in the Mouse
Published on: October 26, 2017
Cardiac hypertrophy drives PGC-1α suppression associated with enhanced O-glycosylation
Robert E Brainard1, Heberty T Facundo2
1Institute of Molecular Cardiology, Department of Medicine, University of Louisville, KY, USA; Department of Physiology and Biophysics, University of Louisville, KY, USA.
Insights
O-linked β-N-acetylglucosamine (O-GlcNAc) signaling suppresses peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) during cardiac hypertrophy. Reducing O-GlcNAc restores PGC-1α activity, revealing a novel regulatory mechanism in heart disease.
Area of Science:
- Molecular Biology
- Metabolic Regulation
- Cardiovascular Physiology
Background:
- Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is crucial for cardiac function and metabolism.
- Cardiac hypertrophy suppresses PGC-1α, contributing to disease morbidity.
- The role of O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in this process is unknown.
Purpose of the Study:
- To investigate the hypothesis that O-GlcNAc signaling regulates PGC-1α suppression during cardiac hypertrophy.
- To elucidate the interplay between O-GlcNAc modification and PGC-1α activity in the heart.
Main Methods:
- Neonatal rat cardiomyocytes were treated with phenylephrine to induce hypertrophy.
- Mice underwent transverse aortic constriction to model cardiac hypertrophy.
- Quantitative real-time PCR was used to assess gene expression.
- O-GlcNAc signaling was modulated using glucosamine and PUGNAC.
Main Results:
- Phenylephrine treatment increased O-GlcNAc signaling and downregulated PGC-1α and mitochondrial genes.
- Transverse aortic constriction reduced PGC-1α expression; reducing O-GlcNAc alleviated this suppression.
- Augmenting O-GlcNAc signaling inhibited PGC-1α upregulation during glucose starvation.
- PGC-1α was found to be directly O-GlcNAcylated.
Conclusions:
- O-GlcNAc signaling acts as a novel regulator of PGC-1α activity in cardiac hypertrophy.
- O-GlcNAc may constitutively suppress PGC-1α activity in the heart.
- These findings suggest implications for metabolic dysregulation in cardiac diseases and inter-regulation of signaling pathways.
Abstract:
The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function. Its activity is suppressed during pressure overload induced cardiac hypertrophy and such suppression at least partially contributes to the associated morbidity. The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal. The relationship between O-GlcNAc, and PGC-1α activity in cardiac hypertrophy is unknown. We hypothesized that hypertrophy-induced suppression of PGC-1α was at least partially regulated by O-GlcNAc signaling. Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling. Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes. Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes. Reduction of O-GlcNAc signaling alleviated suppression of PGC-1α and most of its downstream genes. Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy. Finally, we found that PGC-1α itself is O-GlcNAcylated. Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy. Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart. Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Proteoglycans
Cardiomyopathy III: Hypertrophic Cardiomyopathy
cAMP-dependent Protein Kinase Pathways
GPCR Desensitization
Cardiomyopathy II: Dilated Cardiomyopathy